Breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Omega 3 capsules 2 g daily (twice a day orally) for 4 weeks provided by Zahravi pharmaceutical Company, and then baseline and 4-weeks follow-up demographic data an
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult women suffering from hormone-positive breast cancer with grade I to III who are receiving Selective estrogen receptor modulators (SERM) or Aromatase inhibitors (AIs) family drug. Patients who are complaining from hot flash ( at least 4 times in a previous month) Patients who have compliance and ability to take omega 3 orally
Exclusion criteria
Exclusion criteria: Patients who are in metastatic stage Patients who have a history of other malignancies except for breast cancer Patients who are receiving antipsychotic, anti-depression, anti-anxiolytic, sedative or hypnotic or anti-epileptic drugs Patients with a history of hypersensitivity reaction to omega 3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount and severity of hot flash. Timepoint: Before intervention and 4 weeks. Method of measurement: Menopause Rating Scale (MRS) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual function. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Female Sexual Function Index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Moghaddas
Esfahan University of Medical Sciences
Outcome results
None listed